Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2
Completed
- Conditions
- COVID-19SARS-CoV-210047438
- Registration Number
- NL-OMON52416
- Lead Sponsor
- RIVM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 11229
Inclusion Criteria
Subject previously participated in the PIENTER 3 study (2016/17), and had
indicated that they could be approached for a follow-up study, or subjects from
a random age-stratified sample from the Netherlands
Exclusion Criteria
not applicable
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To assess achieved immunity against COVID-19 over time across the different age<br /><br>groups in The Netherlands by testing a representative part of the Dutch<br /><br>population for the presence of SARS-Cov-2 specific antibodies in serum </p><br>
- Secondary Outcome Measures
Name Time Method <p>To assess the quantity and quality (i.e. antibody functionality and avidity) of<br /><br>the antibodies raised against SARS-CoV-2 in a representative part of the Dutch<br /><br>population, and to identify subgroups (including risk groups) with different<br /><br>levels of immunity against COVID-19<br /><br><br /><br>To assess the development of immunity during and after the first pandemic wave<br /><br>and the period thereafter<br /><br><br /><br>To assess the existence of cross-reactive antibodies against established<br /><br>coronavirus infections in the past<br /><br><br /><br>To asses the antibodies in the mucosal fluid</p><br>